Executive Interview – Adherium

Executive Interview – Adherium

Adherium (ADR.ASX) is an ASX-listed digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Adherium’s market-leading Smartinhaler platform has been independently proven to improve adherence to inhaled medications and improve health outcomes in chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). With an existing 10-year commercial product development and supply agreement with AstraZeneca (AZN) and strong relationships with other global pharmaceutical and medical technology companies and key opinion leaders (KOLs) through sales into the clinical trial sector, Adherium is positioned for strong revenue growth. The company listed on the ASX in August 2015, raising A$35m at A$0.50/share, including a US$3m investment by AZN.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.